# Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

> **NCT03032614** · PHASE2 · WITHDRAWN · sponsor: **The University of Texas Health Science Center at San Antonio**

## Conditions studied

- Breast Cancer Stage IV
- Ovarian Cancer
- BRCA1 Mutation
- BRCA2 Mutation

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Eribulin
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT03032614
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-09-30
- **Primary completion:** 2019-03-31
- **Final completion:** 2020-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2017-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03032614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03032614, "Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03032614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*